GlobalRPh Renal Dosing Masterv6.6
Evidence addition

Deferasirox - EXJADE tablets for oral suspension

Local official-label summaryBase record retrieved 2026-09-10See the evidence for this drug2 sources available - open source summaries, references and comparisons

EXJADE / deferasirox tablets for oral suspension

READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Cautions / source differences (1)
Review first - source-specific qualification

Distinguish initial renal reduction from treatment-emergent injury

The mirror and dated manufacturer PDF agree on selected baseline restrictions. Subsequent injury actions depend on indication and age.

Before applying: Keep EXJADE separate from JADENU. Reconcile current labeling and assess glomerular/tubular injury rather than applying the starting-dose reduction to every situation.

Evidence for this qualification

Selected-source qualification; independent clinician review pending.

Confirm the product, indication and renal measure. The selected summary is not a complete prescribing monograph.

Choose a source to read (2)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

Official source

Deferasirox - EXJADE tablets for oral suspension

Product / population
EXJADE tablets dispersed for oral administration; indication- and age-specific iron chelation. Not a mg-for-mg JADENU regimen.
Renal measure
Indexed eGFR; validated age-appropriate equations; not Cockcroft-Gault substitution
Before using this finding

Dated manufacturer evidence remains visible; verify the current applicable product before prescribing.

Selected named sections only; not a complete monograph or independent clinical approval.

Selected exact-product labeling sections read. Original-source bytes and complete revision histories were not retained or reconciled; retrieval does not establish current product availability.

Renal dosing, restrictions and evidence limits

The July 2020 manufacturer PDF contraindicates eGFR <40 mL/min/1.73 m2 and reduces the starting dose by 50% at 40-60. Evaluate renal glomerular and tubular function before starting or increasing therapy. Monitor eGFR and tubular toxicity weekly in the first month after initiation or modification and at least monthly thereafter; renal-risk patients need more frequent assessment. Pediatric volume-depleting illness requires interruption and reassessment before resumption. On-treatment dose modifications remain indication- and age-specific. The dated PDF is not proof that a full current-label reconciliation has been completed.

Source revision: 7/2020 | Retrieved: 2026-09-10. Retrieval date is not the revision date.

Source: https://www.novartis.com/us-en/sites/novartis_us/files/exjade.pdf

Scope: Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph. GlobalRPh v6.6.

Full source card / provenance

All sources, comparison tools and evidence navigation
Source-specific interpretation

What the dialysis evidence actually supports

Removal information alone does not define a maintenance dose, supplemental dose or dialysis schedule. A reported regimen still requires its product, indication, renal measure and dialysis assumptions to match the patient.

Deferasirox - EXJADE tablets for oral suspension

Authored v6.0; retrieved 2026-09-10 - retained source, not freshly reviewed in this release

No dialysis regimen established in selected content

Read the source and its limits

GlobalRPh RX List - EXJADE

Authored v6.0; retrieved 2026-09-10 - retained source, not freshly reviewed in this release

No dialysis regimen established in selected content

Read the source and its limits

These manual classifications apply only to the identified selected sections, not every retained source or the entire prescribing information. They are not dosing clearance.

Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Read 1 source difference / applicability notes

Official product label

Deferasirox - EXJADE tablets for oral suspension

Restriction or avoidance guidance. Read the specific threshold, age, formulation and dialysis exclusions; do not generalize across products.
Before using this finding

Dated manufacturer evidence remains visible; verify the current applicable product before prescribing.

Dialysis evidence: No dialysis regimen established in selected content

EXJADE tablets dispersed for oral administration; indication- and age-specific iron chelation. Not a mg-for-mg JADENU regimen.

Renal method: Indexed eGFR; validated age-appropriate equations; not Cockcroft-Gault substitution
Retrieved: 2026-09-10

Read local renal resultOpen original reference
GlobalRPh RX List

GlobalRPh RX List - EXJADE

Restriction or avoidance guidance. Read the specific threshold, age, formulation and dialysis exclusions; do not generalize across products.
Before using this finding

Distinguish baseline starting-dose reduction from treatment-emergent injury, indication, age and formulation.

Dialysis evidence: No dialysis regimen established in selected content

EXJADE tablets dispersed for oral administration; indication- and age-specific iron chelation. Not a mg-for-mg JADENU regimen.

Renal method: Indexed eGFR in mL/min/1.73 m2; adult/pediatric equations remain population-specific
Retrieved: 2026-09-10

Read local renal resultOpen original reference

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Product / population check

Confirm the exact formulation before using a renal source

These links compare product identities, not interchangeable doses. A selected summary is not a complete prescribing monograph.

Source-specific review points

Distinguish initial renal reduction from treatment-emergent injury

Read the attributed comparison notes and source cards below. No conflict has been silently adjudicated.

Source-quality holds
Find text within this drug
Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. Searches stay on this page and are not saved or sent.

All source summaries, original wording and provenance
Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources
Jump to renal guidanceRead 1 difference / caution notesClinician guide

Select two distinct source versions. The complete stored summaries will appear below.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Read before choosing a regimen

Source differences and product cautions

Search differences across all drugs

These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.

dated label and multiple adjustment context

Distinguish initial renal reduction from treatment-emergent injury

The mirror and dated manufacturer PDF agree on selected baseline restrictions. Subsequent injury actions depend on indication and age.

How to use this: Keep EXJADE separate from JADENU. Reconcile current labeling and assess glomerular/tubular injury rather than applying the starting-dose reduction to every situation.

GlobalRPh RX List - EXJADEDeferasirox - EXJADE tablets for oral suspensionDeferasirox (JADENU / JADENU SPRINKLE)

Source-specific interpretation; independent clinician adjudication pending.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

New source summary - independent clinical review pending. Summaries of the identified label sections are included locally. Source import and numeric transcription checks are not independent two-reference validation. Do not treat this card as an approved institutional dosing protocol.

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Original content / product scopeDeferasirox - EXJADE tablets for oral suspensionGlobalRPh RX List - EXJADE
Choose two source checkboxes below.
Exact product and population matter. This added page contains locally stored, source-specific clinical summaries. Historical handbook information, when present, is identified separately and may conflict with U.S. labeling. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.
Locally stored source content

Exact product and population

Product identity selected for the separately displayed source protocols below. Reference: https://globalrph.com/rx-list/exjade-drug/

Exact product and population

EXJADE tablets dispersed for oral administration; indication- and age-specific iron chelation. Not a mg-for-mg JADENU regimen.

RDM60-SCOPE-deferasirox-exjade · Source section: Selected source product scopeRenal section finder
Separate U.S. product-label layer

FDA / DailyMed dosing and renal information

Official

Deferasirox - EXJADE tablets for oral suspension

Open original reference

Open / share this exact local source

Novartis Pharmaceuticals Corporation / manufacturer prescribing information · EXJADE tablets dispersed for oral administration; indication- and age-specific iron chelation. Not a mg-for-mg JADENU regimen.

Renal method: Indexed eGFR; validated age-appropriate equations; not Cockcroft-Gault substitution
Source date: 7/2020
Retrieved: 2026-09-10

Restriction or avoidance guidance. Read the specific threshold, age, formulation and dialysis exclusions; do not generalize across products.
Before using this finding

Dated manufacturer evidence remains visible; verify the current applicable product before prescribing.

Dialysis evidence: No dialysis regimen established in selected content

Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

The July 2020 manufacturer PDF contraindicates eGFR <40 mL/min/1.73 m2 and reduces the starting dose by 50% at 40-60. Evaluate renal glomerular and tubular function before starting or increasing therapy. Monitor eGFR and tubular toxicity weekly in the first month after initiation or modification and at least monthly thereafter; renal-risk patients need more frequent assessment. Pediatric volume-depleting illness requires interruption and reassessment before resumption. On-treatment dose modifications remain indication- and age-specific. The dated PDF is not proof that a full current-label reconciliation has been completed.

RDM60-official-deferasirox-exjade-bc4f674e76-C1 · Source locator: 2.4-2.5 and 5.1; PDF pages 6 and 8 rendered

Source-specific limits

Selected named sections only; not a complete monograph or independent clinical approval.

Selected exact-product labeling sections read. Original-source bytes and complete revision histories were not retained or reconciled; retrieval does not establish current product availability.

Source identity and provenance
Source family
product_label
Source
https://www.novartis.com/us-en/sites/novartis_us/files/exjade.pdf
Retrieved
2026-09-10
Exact label title
Deferasirox - EXJADE tablets for oral suspension
Labeler
Novartis Pharmaceuticals Corporation
Label revision
7/2020
Renal-function method
Indexed eGFR; validated age-appropriate equations; not Cockcroft-Gault substitution
Source date/version
7/2020
Hash meaning
SHA-256 of local authored summary only; not original HTML, PDF or SPL bytes.
Local summary SHA-256
ad8dfab8321d1ecc1814c281330dcdd2ef7c13d3ba0af50a5b8621f1a0552743
Locally imported selected renal sections

GlobalRPh RX List renal information

Rxlist

GlobalRPh RX List - EXJADE

Open original reference

Open / share this exact local source

GlobalRPh-hosted RX List · EXJADE tablets dispersed for oral administration; indication- and age-specific iron chelation. Not a mg-for-mg JADENU regimen.

Renal method: Indexed eGFR in mL/min/1.73 m2; adult/pediatric equations remain population-specific
Source date: Source revision date not established in selected retrieval.
Retrieved: 2026-09-10

Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Restriction or avoidance guidance. Read the specific threshold, age, formulation and dialysis exclusions; do not generalize across products.
Before using this finding

Distinguish baseline starting-dose reduction from treatment-emergent injury, indication, age and formulation.

Dialysis evidence: No dialysis regimen established in selected content

Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

The mirror contraindicates eGFR below 40 mL/min/1.73 m2 and reduces the starting dose by 50% at 40-60. On-treatment renal actions are separately organized by indication and age; they must not be collapsed into the starting-dose rule. Assess both glomerular and tubular injury. Pediatric volume-depleting illness calls for interruption and more frequent monitoring, with renal function, intake and volume status assessed before resumption. This selected summary does not supply a combined adjustment algorithm.

RDM60-rxlist-deferasirox-exjade-0053d094ad-C1 · Source locator: 2.4; 2.5; 5.1

Source-specific limits

Selected named sections only; not a complete monograph or independent clinical approval.

A label mirror is not independent corroboration of its underlying label. See the separately attributed official source; concordance is limited to selected sections.

Source identity and provenance
Source family
product_label_mirror
Source
https://globalrph.com/rx-list/exjade-drug/
Retrieved
2026-09-10
Renal-function method
Indexed eGFR in mL/min/1.73 m2; adult/pediatric equations remain population-specific
Source date/version
Source revision date not established in selected retrieval.
Hash meaning
SHA-256 of local authored summary only; not original HTML, PDF or SPL bytes.
Local summary SHA-256
58947842b00e798d80ed1bee6053ac05616c36b8b6b086587cfdceb837714a26

Provenance and preservation

Additional summaries stored on this page: 1 official-label, 1 RX List, 0 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source
https://globalrph.com/rx-list/exjade-drug/
Source retrieval
2026-09-10. This is not the source publication or label revision date.
Original source type
rxlist summary
Local text SHA-256
55ddb43e70d41fd85b067bdfd1e8767d321a1f312c0c6d38e46ded104e2a0235
Import versus clinical validation
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

This page is an additional exact-product entry, not a recovered GlobalRPh monograph. Its primary scope text and separately attributed clinical summaries are locally included.

Read the full coverage report